Nuvectis Pharma, Inc. · NASDAQ:NVCT

Nuvectis Pharma — Investor Presentation (May 2026)

27 slides from Nuvectis Pharma's investor presentation, May 2026

  1. Slide 1: Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology (NASDAQ: NVCT) May 2026

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Nuvectis Pharma, Inc This presentation contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in

  3. Slide 3: Nuvectis Pharma – Key Highlights

    Nuvectis Pharma – Key Highlights Our Approach to NXP900 Management Team with Precision Medicine Strong Track Record Select and acquire novel, Phase 1a dose escalation and DDI 3 approved drugs in 4 rationally-designed targeted studies completed, Phase 1b indications in the US and EU therapy drug cand

  4. Slide 4: Management Team

    Management Team Track record of success Ron Bentsur Enrique Poradosu, PhD Shay Shemesh Chairman & Chief Executive Officer Chief Scientific & Business Officer Chief Development & Operations Officer Jelmyto® (mitomycin) NuvectisPharma, Inc. 4

  5. Slide 5: NXP900: A Pipeline in a Pill Opportunity

    Addressing large markets within the precision medicine space in oncology NXP900: A Pipeline in a Pill Opportunity

  6. Slide 6: NXP900 Key Highlights

    NXP900 Key Highlights Precision Medicine Approach Differentiated Features Phase 1 Program Discovered at the University of Highly selective Phase 1a dose escalation and Edinburgh, Scotland Unique mechanism of action - DDI clinical trials completed A potent, novel, small molecule Complete shut-down of

  7. Slide 7: NXP900 Kinome Profiling Demonstrates High Selectivity

    NXP900 Kinome Profiling Demonstrates High Selectivity NXP900 Dasatinib Note: Dasatinib data from Remsing Rix et al., Leukemia 23, 477–485 (2009), NXP900 data from AACR 2022. NuvectisPharma, Inc. 7

  8. Slide 8: NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family

    NXP900 Completely Shuts Down Signaling of Non-receptor Tyrosine Kinases of the SRC Family Differentiated vs. other multi-kinase inhibitors that only achieve partial SRC pathway shut down SRC-NXP900 co-crystal structure SRC-dasatinib co-crystal Binding to YAP Binding to FAK, CAS, paxillin, etc. Dasat

  9. Slide 9: NXP900 Clinical Progress

    NXP900 Clinical Progress Phase 1a dose escalation study completed (7 dose cohorts: 20 – 300 mg/day QD) in patients with advanced solid tumor patients (“all comers”) Safety Profile Pharmacodynamics Starting dose Acceptable safety Robust PD response selected for Part B: with DLT dose level with approx

  10. Slide 10: NXP900 Phase 1a: Preliminary Summary of Common TEAEs (N=33)

    NXP900 Phase 1a: Preliminary Summary of Common TEAEs (N=33) Adverse Event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total N (%) Diarrhea 7 (21) 7 (21) 1 (3) 0 (0) 0 (0) 15 (45) Fatigue 4 (12) 9 (27) 2 (6) 0 (0) 0 (0) 15 (45) Nausea 7 (21) 5 (15) 0 (0) 0 (0) 0 (0) 12 (36) Decreased appetite 2 (6) 8 (24

  11. Slide 11: Pharmacodynamic Activity in Phase 1a

    Pharmacodynamic Activity in Phase 1a Treatment with NXP900 results in robust and consistent inhibition of SRC autophosphorylation Treatment with NXP900 resulted in substantial reduction of pSRC in peripheral blood mononuclear cells (PBMCs) (pooled analysis of available data across the dose range at

  12. Slide 12: Clinical Drug-drug Interaction (DDI) Study: Supports Combination Strategy

    Clinical Drug-drug Interaction (DDI) Study: Supports Combination Strategy Key Pharmacokinetics Result: ✓ NXP900 increased the concentration of midazolam, a known CYP3A sensitive substrate, by < 2-fold, classifying it as a weak inhibitor of CYP3A Study Population: 14 healthy volunteers ✓ NXP900 incre

  13. Slide 13: Single Agent Strategy Rationale

    Single Agent Strategy Rationale Hippo pathway mutations and YES1 gene amplification are associated with sensitivity to NXP900 Mechanistic Rationale Preclinical POC In Vivo HCC95 Xenograft SW900 Xenograft Lung Squamous, YES1 amplification Lung Squamous, FAT1 mutation KYSE70 Xenograft CAL27 Xenograft

  14. Slide 14: Validation of SRC as a Clinical Target in NSCLC

    Validation of SRC as a Clinical Target in NSCLC Saracatinib case study ❖ Saracatinib was developed as a target-specific SRC inhibitor ❖ Saracatinib was clinically active at a dose of 175 mg/day (the RP2D) in a clinical study in ~25 patients with NSCLC (not enriched for specific genetic alterations)

  15. Slide 15: NXP900: Phase 1b Program

    NXP900: Phase 1b Program

  16. Slide 16: NXP900 Phase 1b Ongoing

    NXP900 Phase 1b Ongoing Monotherapy Cohorts* Combinations #1: NSCLC (adenocarcinoma): YES1, TYMS, FAT1 #1: NSCLC: EGFR mutated, previous response to #2: NSCLC (SCC): YES1, TYMS, FAT1 Osimertinib - ongoing #3: Renal cancer: NF2 #2: NSCLC: ALK fusion, previous response to lorlatinib #4: Mesothelioma:

  17. Slide 17: NXP900 Combination Opportunities

    NXP900 Combination Opportunities Targeting resistance to ALK/EGFR TKIs in NSCLC ALK Resistance EGFR Resistance NXP900 + lorlatinib - Low nanomolar synergy in lorlartinib NXP900 + osimertinib - reversed acquired resistance to resistant cell lines osimertinib in resistant cell lines NCI-H2228-AleR1 NC

  18. Slide 18: NXP900 Combination With RAS Inhibitors

    NXP900 Combination With RAS Inhibitors SRC activation is involved in multiple pathways leading to acquired resistance to Ras inhibition (AACR 2026) NCI-H23 NCI-H23 SotR2 NCI-H23 SotR3 ZIP 75% Quantile: 7.6 ZIP 75% Quantile: ZIP 75% 23.14 Quantile: 20.54 ❖ SRC, YES1 and YAP1 activation have been vali

  19. Slide 19: Phase 1b Program: Combination Study

    Phase 1b Program: Combination Study NXP900 will be evaluated in combination with EGFR and ALK inhibitors in patients with NSCLC who initially responded, and became resistant to, treatment with EGFR/ALK TKIs EGFR/ALK TKIs are Acquired resistance Extensive scientific Broad preclinical highly effective

  20. Slide 20: NXP900: Significant Market Opportunity

    NXP900: Significant Market Opportunity

  21. Slide 21: NXP900 Single Agent Market Opportunity

    NXP900 Single Agent Market Opportunity Addressable patient potential supported by potent in vivo activity in lung, esophageal and head and neck cancer models FAT1 mutations/deletions YES1 amplifications FAT1 and YES1 alterations affect Bladder 6,872 Esophageal 1,132 >41,000 patients NSCLC 11,353 NSC

  22. Slide 22: Mutations Play a Major Role Guiding NSCLC Treatment

    Mutations Play a Major Role Guiding NSCLC Treatment Approximately 200K newly diagnosed U.S. NSCLC patients, 2026* EGFR ALK R ET/ROS Targeted therapy opportunity: ~30-52K 10 - 15% 3 - 7% 2 - 4% Incidence ~20-30K ~6-14K ~4-8K *Based on ~229K newly diagnosed lung cancer patients, including 80-85% of pa

  23. Slide 23: Financial and Corporate Highlights

    Financial and Corporate Highlights

  24. Slide 24: Financial Highlights and Upcoming Milestones

    Financial Highlights and Upcoming Milestones Selected Financial Highlights Financial Information Ticker NVCT Cash $25.1 million as of March 31, 2026 Insider Ownership Founders and >5% holders Approximately 40% 2026 Expected Milestones Program Milestone NXP900 ▪ Multiple clinical data updates from th

  25. Slide 25: Research Coverage

    Research Coverage Roth-MKM Jonathan Aschoff Lucid Capital Markets Christopher Liu Laidlaw & Company Yale Jen Maxim Group Naz Rahman H.C. Wainwright Joe Pantginis NuvectisPharma, Inc. 25

  26. Slide 26: Nuvectis Pharma – Key Highlights

    Nuvectis Pharma – Key Highlights Our Approach to NXP900 Management Team with Precision Medicine Strong Track Record Select and acquire novel, Phase 1a dose escalation and DDI 3 approved drugs in 4 rationally-designed targeted studies completed, Phase 1b indications in the US and EU therapy drug cand

  27. Slide 27: Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. Innovative Precision Medicine for Serious Conditions of Unmet Medical Need in Oncology (NASDAQ: NVCT) May 2026

Nuvectis Pharma — Investor Presentation (May 2026) on 6ix